Maryanna Polukhin, MD
Internal Medicine · Newington, CTNPI 1881688034
Payments from drug & device makers
Across 182 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$841
- AstraZeneca$351
- Pfizer$350
- Boehringer Ingelheim$270
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$201
- Lilly USA, LLC$151
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,42999%
- Other$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $841 |
| AstraZeneca | 18 | $351 |
| Pfizer | 17 | $350 |
| Boehringer Ingelheim | 12 | $270 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $201 |
| Lilly USA, LLC | 8 | $151 |
| Astellas Pharma US Inc | 6 | $113 |
| Novo Nordisk | 4 | $92 |
| Eisai Inc. | 4 | $66 |
| Exeltis, USA Inc. | 3 | $66 |
| Merck | 4 | $64 |
| Almatica Pharma LLC | 3 | $63 |
| Johnson & Johnson | 3 | $61 |
| Abbott | 3 | $60 |
| GSK | 3 | $56 |
| Exact Sciences | 3 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
| Novartis | 2 | $47 |
| Amgen | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Ardelyx, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Upsher-smith Laboratories LLC | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| VBI Vaccine (delaware) Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Myovant Sciences Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $16 |
| Welch Allyn | 1 | $15 |
| Alk-abello, Inc | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $13 |
How this compares
$3,463 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $159,218 |
| EliquisApixaban | 90 | $116,162 |
| JanuviaSitagliptin Phosphate | 45 | $74,198 |
| LinzessLinaclotide | 61 | $73,304 |
| XareltoRivaroxaban | 27 | $38,772 |
| JardianceEmpagliflozin | 22 | $35,930 |
| TrulicityDulaglutide | 26 | $34,626 |
| RybelsusSemaglutide | 24 | $32,326 |
| FarxigaDapagliflozin Propanediol | 18 | $31,275 |
| MounjaroTirzepatide | 23 | $27,064 |
| CreonLipase/Protease/Amylase | 20 | $21,556 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $20,298 |
| GemtesaVibegron | 22 | $17,314 |
| OxycontinOxycodone Hcl | 12 | $17,085 |
| MyrbetriqMirabegron | 15 | $15,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $92 | $191,544168 claims |
| PfizerEliquis | $350 | $116,16290 claims |
| AbbVieLinzess, Creon, Synthroid | $841 | $99,118125 claims |
| MerckJanuvia, Janumet | $64 | $94,49657 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $151 | $61,68949 claims |
| Johnson & JohnsonXarelto | $61 | $38,77227 claims |
| Boehringer IngelheimJardiance | $270 | $35,93022 claims |
| AstraZenecaFarxiga | $351 | $31,27518 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $56 | $25,43638 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $54 | $17,31422 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $15,61715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Newington
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.